TP53 and hepatocellular carcinoma: The viability of tailored neoantigen-based vaccines in HCC has been supported by recent multi-omics and immunopeptidomics studies that have identified naturally presented neoepitopes in HCC, including those derived from driver-mutated genes such as TP53 and CTNNB1 [239].